maccura(SZ:300463) Sou Hu Cai Jing·2025-06-26 10:17Group 1 - The core viewpoint of the articles indicates that Maike Biological's stock is currently trading at a high PE ratio of 236.77, significantly above the industry average of 49.45 [1][3] - As of March 31, 2025, the number of shareholders in Maike Biological has decreased to 35,022, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The latest financial results for Q1 2025 show a revenue of 510 million yuan, representing a year-on-year decline of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year, with a gross margin of 56.76% [2] Group 2 - Maike Biological specializes in the research, production, sales, and related services of in vitro diagnostic products, with a wide range of testing reagents for various medical conditions [2] - The company ranks 118th in terms of PE ratio within the medical device industry, which has a median PE of 35.92 [1][3] - The industry average PE ratio is 49.45, while the average price-to-book ratio is 4.57, indicating a higher valuation compared to Maike Biological's metrics [3]